Biocom California: Next Gen Autologous Cell Therapy Approaches
September 8 @ 4:00 pm - 6:00 pm
The Biocom California Cell & Gene Therapy Committee brings together members working in the cell therapy and gene therapy space to share ideas and best practices, and gain common understanding of this important therapeutic field to drive innovation and manufacturing approaches forward.
Committees are open to Biocom California industry member companies actively engaged in cell and/or gene therapy. If you are a service provider member working in the space and would like to attend, please contact firstname.lastname@example.org to inquire.
Join us for a conversation on Next Gen Autologous Cell Therapy Approaches followed by a Q&A session and a networking reception.
The interactive panel discussion will focus on:
• Shortening or skipping ex-vivo cell expansion; can we get from factories to point of care therapy?
• New approaches to gene editing and non-viral approaches
• Combining T cell engagers with universal CAR
• Other more exotic approaches
Jeff Bluestone, CEO and President, Sonoma Biotherapeutics
Jens Vogel, Senior Vice President and Global Head of Biotech, Bayer Pharmaceuticals
Jackson Egen, Vice President, Oncology Research, Gilead Sciences
Kole T. Roybal, Associate Professor | Microbiology & Immunology, UCSF, Parker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub Investigator, Helen Diller Family Comprehensive Cancer Center
- September 8
4:00 pm - 6:00 pm